Journey Medical Q2 revenue $15.0M; Emrosi sales $2.8M in first full quarter

Journey Medical Corp

2025-Q2 EPS reported -$0.34 vs consensus -$0.11 ▼ miss (-217.5%)

Net loss of $3.8M ($0.16 EPS) vs $3.4M loss ($0.17 EPS) in Q2 2024.
Total net product revenue $15.0M, up slightly from $14.9M year-over-year.
Gross margin improved to 67% from 61% due to favorable product mix and lower COGS.
SG&A expenses rose to $11.9M from $10.3M, driven by Emrosi launch costs.
Adjusted EBITDA loss of $0.5M vs positive $0.3M in prior year period.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.